Eledon Pharmaceuticals, Inc. (ELDN) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-91.0%

$0.24

vs $2.62 price

Levered DCF

$0.27

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-4.22

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-2.7×	-5.49×	-0.38×	-0.37×	-1.89×	-0.9×	-0.43×	-1.02×
P/B	1.52×	1.69×	6.15×	0.39×	0.4×	1.22×	13.01×	17.9×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-2.24×	-5.1×	-0.35×	0.59×	0.51×	-7.46×	-7.25×	-17.54×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	7.4×	12.42×	14.41×	9.19×	20.07×	46.57×	7.54×	5.63×
Debt / equity	0.01×	0.01×	0.05×	0.01×	0×	0×	0.03×	0×
Interest coverage	0×	0×	0×	0×	0×	-1.91×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	-0.1%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-56.3%	-30.6%	-1616.8%	-104.5%	-21.0%	-12.0%	-169.2%	-97.1%
Return on invested capital	-55.1%	-42.5%	-50.3%	-102.0%	-20.7%	-9.3%	-144.9%	-97.0%
Return on assets	-27.0%	-20.4%	-130.8%	-94.8%	-20.2%	-11.6%	-146.5%	-82.6%
Free cash flow yield	-50.4%	-23.6%	-89.2%	-87.3%	-44.2%	-6.5%	-11.2%	-4.6%
Earnings yield	-36.9%	-18.1%	-263.0%	-270.1%	-52.8%	-9.8%	-13.0%	-5.4%
Enterprise value	$101.4M	$180.4M	$40.1M	-$23.1M	-$18.7M	$119.4M	$114.7M	$246.4M
Net debt / EBITDA	0.49×	0.55×	0.04×	1.41×	2.29×	7.13×	0.53×	0.92×
Cash conversion cycle (days)	0	0	0	0	0	0	1,107	-22,862